Insilico Sees Rising Revenue From Deals With AI Firms

Insilico Medicine reported rising revenue from agreements with artificial intelligence firms, according to Bloomberg. Alex Zhavoronkov, founder and CEO of the drug discovery company, discussed the firm's earnings and business outlook in an interview on Bloomberg: The China Show. The company develops artificial intelligence tools for pharmaceutical research and development.

Next story